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ABSTRACT
Introduction For people with type 2 diabetes mellitus 
(T2DM) who require an antidiabetic drug as an add- on to 
metformin, there is controversy about whether newer drug 
classes such as dipeptidyl peptidase- 4 inhibitors (DPP4i) 
or sodium- glucose co- transporter- 2 inhibitors (SGLT2i) 
reduce the risk of long- term complications compared with 
sulfonylureas (SU). There is widespread variation across 
National Health Service Clinical Commissioning Groups 
(CCGs) in drug choice for second- line treatment in part 
because National Institute for Health and Care Excellence 
guidelines do not specify a single preferred drug class, 
either overall or within specific patient subgroups. This 
study will evaluate the relative effectiveness of the three 
most common second- line treatments in the UK (SU, DPP4i 
and SGLT2i as add- ons to metformin) and help target 
treatments according to individual risk profiles.
Methods and analysis The study includes people with 
T2DM prescribed one of the second- line treatments- of- 
interest between 2014 and 2020 within the UK Clinical 
Practice Research Datalink linked with Hospital Episode 
Statistics and Office of National Statistics. We will use 
an instrumental variable (IV) method to estimate short- 
term and long- term relative effectiveness of second- line 
treatments according to individuals’ risk profiles. This 
method minimises bias from unmeasured confounders by 
exploiting the natural variation in second- line prescribing 
across CCGs as an IV for the choice of prescribed 
treatment. The primary outcome to assess short- term 
effectiveness will be change in haemoglobin A1c (%) 12 
months after treatment initiation. Outcome measures to 
assess longer- term effectiveness (maximum ~6 years) will 
include microvascular and macrovascular complications, 
all- cause mortality and hospital admissions during follow- 
up.
Ethics and dissemination This study was approved by 
the Independent Scientific Advisory Committee (20- 064) 
and the London School of Hygiene & Tropical Medicine 
Research Ethics Committee (21395). Results, codelists 
and other analysis code will be made available to patients, 
clinicians, policy- makers and researchers.
INTRODUCTION
Around 3.5 million people in the UK have 
been diagnosed with type 2 diabetes mellitus 
(T2DM) accounting for ~10% of National 
Health Service (NHS) expenditure.1 This 
proportion is predicted to rise to ~17% by 
2035–2036.2 T2DM is a progressive disease 
which requires careful management of blood 
glucose and diabetes- associated complica-
tions.1 The National Institute for Health 
and Care Excellence (NICE) recommends 
metformin as the first- line antidiabetic treat-
ment in people with T2DM.1 In many cases, 
people with T2DM need further treatment in 
addition to metformin monotherapy to main-
tain sufficient glycaemic control.
NICE guidance recommends several drug 
classes as add- ons to metformin for first- 
stage intensification, hereafter referred to as 
second- line treatment. These include sulfo-
nylureas (SU), pioglitazone, dipeptidyl pepti-
dase- 4 inhibitors (DPP4i) or sodium- glucose 
Strengths and limitations of this study
 ► This large representative study of UK clinical prac-
tice will describe variation in second- line antidiabet-
ic treatment for people with type 2 diabetes mellitus.
 ► The instrumental variable (IV) design will minimise 
bias due to confounding by indication and provide 
person- level estimates of second- line treatment 
effectiveness.
 ► The IV design relies on assumptions which can only 
be partly tested using the data available.
 ► We will not consider less commonly used inject-
able second- line antidiabetic treatments in the UK, 
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co- transporter- 2 inhibitors (SGLT2i).1 3 NICE guidance 
recommends considering individual clinical circum-
stances when selecting T2DM drug treatment. For 
instance, SGLT2i are recommended as second- line treat-
ment if the person is at high risk of hypoglycaemia or when 
SU are not tolerated or are contraindicated.1 3 However, 
these guidelines do not specify a single preferred drug 
class, either overall or within specific groups sharing 
clinical characteristics.1 Research using a representative 
sample of the UK primary care population up to 2017 
showed that SU, DPP4i and SGLT2i, each in combina-
tion with metformin, are the most commonly prescribed 
second- line treatments.4
There is wide variation in the proportion of people 
prescribed these drugs in addition to metformin across 
NHS Clinical Commissioning Groups (CCGs), who 
commission local NHS services, suggesting clinician pref-
erence may influence treatment choice.4 In particular, the 
variation in SGLT2i prescribing suggests that some clini-
cians may prescribe these drugs even for those patients 
who are not considered at high risk of hypoglycaemia and 
therefore eligible for SU.
Similar to NICE guidance, an international consensus 
statement published in 2018 did not specify a single 
preferred drug class for second- line treatment, but recom-
mended that choice is ‘personalised’ to individual char-
acteristics and risk profiles. This statement was updated 
in 2019 in light of new evidence supporting SGLT2i or 
glucagon- like peptide- 1 receptor agonist (GLP1RA) use 
after metformin for those with atherosclerotic cardiovas-
cular disease (CVD), or those at high CVD risk.5 However, 
regulators, clinicians and patients remain uncertain 
about how best to tailor second- line antidiabetic treat-
ment based on individual characteristics.
Meta- analyses have reported that compared with 
other antidiabetic treatments, second- generation or 
third- generation SU are not associated with higher risk 
of death or cardiovascular (CV) events.6 7 A recent CV 
outcome trial reported that the safety profile of glime-
piride (SU drug class) was similar to linagliptin (DPP4i 
drug class).8 Several placebo- controlled trials reported 
that SGLT2i reduced major CV events in people with 
T2DM.9–12 While head- to- head randomised controlled 
trials (RCTs) can provide unbiased estimates of rela-
tive effectiveness, the range and number of participants 
included in head- to- head RCTs of alternative second- line 
treatments are insufficient to provide reliable estimates of 
long- term effectiveness according to individual- level risk 
profiles.13–15
Observational studies comparing outcomes of alterna-
tive second- line drug regimens have reported that SU, 
DPP4i and SGLT2i combined with metformin are all 
associated with haemoglobin A1c (HbA1c) reductions 
compared with metformin alone16 17; however, some 
reported that SU are associated with higher risk of CV 
events.7 18 These observational studies did not recognise 
that people who receive SU may have been a more severe 
case mix according to unmeasured prognostic variables 
(eg, frailty) meaning results are likely biased due to 
confounding by indication.19
Aims and objectives
This study aims to investigate the relative effectiveness 
of SU, DPP4i or SGLT2i in combination with metformin 
as second- line antidiabetic drug treatments on key 
T2DM outcomes, and how treatment decisions should 
be tailored to an individual’s risk factor profile to maxi-
mise clinical benefit. We will use advanced quantitative 
methods to minimise the impact of confounding by indi-
cation and allow for heterogeneity according to patient 
characteristics.
The study’s objectives are to: (1) Describe baseline 
characteristics and treatment patterns overall, and by clin-
ically important subgroups, for SU, DPP4i and SGLT2i in 
combination with metformin as second- line T2DM treat-
ment; (2) Estimate the relative short- term (12 month) 
effectiveness of SU, DPP4i or SGLT2i combined with 
metformin on levels of HbA1c, overall and according to 
individual risk- factor profiles and (3) Estimate the long- 
term (maximum ~6 years) effectiveness of SU, DPP4i or 
SGLT2i combined with metformin on incident micro-
vascular and macro- vascular complications, overall and 
according to individual risk- factor profiles.
METHODS AND ANALYSIS
Data resources
We will identify the study population using the UK Clin-
ical Practice Research Datalink (CPRD),20 21 a pseudony-
mised primary care database which includes detailed 
demographic/lifestyle data, clinical diagnoses and 
measurements, primary care prescriptions, referrals and 
laboratory test results for approximately 20% of the UK 
population. Both the CPRD Gold and Aurum datasets will 
be used to identify people eligible for inclusion, providing 
a representative population of people with T2DM eligible 
for the second- line treatments of interest.20 21
Linkage to Hospital Episode Statistics (HES) is avail-
able for approximately 70% of English practices and 
will be used to gather secondary care data for the study 
population. HES Admitted Patient Care data includes 
complete in- patient admissions data to all NHS hospitals 
in England.22 These secondary care data include admis-
sion and discharge dates, diagnoses and other descriptive 
information (eg, ethnicity). Linkages will also be made to 
the Office of National Statistics to obtain mortality data 
and the Index of Multiple Deprivation (IMD) as a person- 
level proxy of socioeconomic status (SES).
Sample selection/study population
The study population will include people registered with 
a CPRD- contributing practice, aged 18 years or older, 
diagnosed with T2DM who intensify antidiabetic treat-
ment from metformin- monotherapy to a combination of 
metformin and SU, DPP4i or SGLT2i (second- line treat-
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We will identify people within CPRD with at least 
one prescription for metformin monotherapy and one 
other antidiabetic medication in primary care between 1 
January 2011 and 31 March 2020, registered at a general 
practice (GP) contributing research- quality data at the 
prescription date, and registered with their GP for at 
least 1 year prior to the first metformin or other antidi-
abetic prescription, to ensure that we are studying new 
users. The study population will be limited to people 
with a T2DM primary care code, on or before the anti-
diabetic index date to exclude those prescribed antidi-
abetic medications for other indications (eg, polycystic 
ovarian syndrome or pre- diabetes). Using the individual’s 
entire prescribing history with their registered GP, we will 
include only people who initiate antidiabetic treatment 
with metformin, and intensify metformin- monotherapy 
with a first- time prescription for one of the three second- 
line antidiabetic drug treatments of interest after 1 January 
2014. We chose this date for the evaluation of these three 
treatments as prior to this only a small minority of people 
in the UK were prescribed SGLT2i.4 People who inten-
sify with two or more drug classes on the same date, who 
discontinue metformin monotherapy prior to a prescrip-
tion for SU, DPP4i or SGLT2i, or who are prescribed a 
different drug class as second- line treatment (eg, thiazoli-
dinedione (TZD), insulin, GLP1RA) will be excluded. In 
addition, we will exclude people with estimated glomer-
ular filtration rate (eGFR) below 30 mL/min/1.73m2 
since SGLT2i are contraindicated for this group.23 We will 
also exclude women who were pregnant in the 12 months 
prior to second- line treatment initiation since prescribing 
guidelines recommend different treatments for pregnant 
and breastfeeding women.24
Exposures
Exposure groups will include people prescribed SU, 
DPP4i or SGLT2i as an add- on to metformin. We will not 
consider other less commonly prescribed T2DM inten-
sification treatments namely TZD, insulin and GLP1- RA 
since these treatments combined account for less than 
10% of second- line therapy regimens in the UK.4
The first prescription date for second- line treatment 
will be considered baseline. To reduce misclassification 
of people who switch treatments rather than add- on to 
metformin, we require an additional prescription for 
metformin on the same date or within 60 days after the 
first prescription for the second- line drug prescription 
(SU, DPP4i or SGLT2i). This follows precedent research 
which used the same definition for second- line antidia-
betic treatment in the same database.4 25 The study will 
take an intention- to- treat approach, where each person 
will contribute to the original exposure group to which 
they were assigned, irrespective of which treatments 
they may be prescribed subsequently. People will remain 
exposed until the date the data are censored by death, 
the patient leaving the GP practice, the GP practice stops 
contributing to CPRD, or 31 July 2020. We will use the 
prescription duration recorded in primary care, plus a 
Figure 1 Flow diagram illustrating the identification of the study cohort of people with type 2 diabetes mellitus (T2DM) who 
initiate second- line antidiabetic treatment with metformin and one of sulfonylurea (SU), dipeptidyl peptidase four inhibitor 
(DPP4i) or sodium- glucose cotransporter two inhibitors (SGLT2i). CPRD, Clinical Practice Research Datalink; eGFR, estimated 
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60- day grace- period to account for stock- piling medi-
cines, to mark the end of a prescription. Where these 
data are missing, we will impute the length of prescrip-
tion with the mean duration of prescription at the prac-
tice level, plus the 60- day grace- period, to mark the end 
of a prescription. Data on subsequent anti- diabetic treat-
ments (third line, fourth line, etc) will be described in 
those who discontinue second- line treatment.
The study requires information on each person’s 
adherence to antidiabetic treatments. First, to provide a 
‘baseline’ measure of adherence, we require a measure 
of each person’s adherence to metformin monotherapy 
in the year prior to second- line treatment. We will then 
assess whether baseline adherence modifies the relative 
effectiveness of the alternative second- line treatments. 
Second, we will calculate treatment adherence during the 
follow- up to help interpret the estimates of the relative 
effectiveness of the alternative second- line treatments. 
For both measures of adherence, we will calculate defined 
daily dose (DDD) from the number of tablets and dosage 
instructions prescribed versus the duration of the period 
in question.
Covariates
We will use primary care demographic data, diagnosis 
codes (Read or SNOMED for CPRD Gold and Aurum, 
respectively), and laboratory test results recorded prior 
to second- line treatment initiation, to define our main 
list of potential confounders. These include age, sex, 
IMD, time on first- line antidiabetic treatment (as a proxy 
for diabetes duration), GP size, relevant coprescriptions 
prescribed within 60 days of second- line treatment initia-
tion (renin- angiotensin system inhibitors, statins), history 
of proteinuria and comorbidities at baseline (myocardial 
infarction (MI), unstable angina, stroke, ischaemic heart 
disease, hypoglycaemia, congestive heart failure (CHF), 
chronic kidney disease (CKD), end- stage renal disease 
(ESRD), cancer (any), advanced eye disease and lower 
extremity amputation). CKD status will be defined using 
serum creatinine test results to derive eGFR, using cut- 
points defined by the Kidney Disease Improving Global 
Outcomes guidelines for CKD, but without requiring two 
measures 3 months apart.26 We will also identify HbA1c, 
systolic blood pressure (SBP), diastolic blood pressure 
(DBP), eGFR, body weight and body mass index (BMI)27 
using values recorded in the 180 days period before the 
second- line antidiabetic treatment initiation date in the 
primary care record. Time between baseline clinical 
measures and second- line treatment initiation will also be 
included as covariates. We will follow previous observa-
tional research,28 in undertaking secondary analyses that 
include additional potential confounders that are defined 
in primary care records, but for which we anticipate 
relatively high levels of missing data, namely: ethnicity, 
high- density lipoprotein (HDL), low- density lipopro-
tein (LDL), total cholesterol, triglycerides, smoking and 
alcohol status. In the HES- linked cohort, we will use Inter-
national Classification of Diseases 10th Revision (ICD- 10) 
diagnosis codes recorded as part of previous hospital-
isations in conjunction with primary care data to define 
comorbidities. We will also use ethnicity recorded in HES 
for people whose ethnicity is missing within the primary 
care data. Codelists for all covariates defined in primary 
and secondary care will be published alongside study 
results.
Outcomes
The primary outcome for objective 2 (short- term relative 
effectiveness) will be absolute change in HbA1c% at 12 
months follow- up. This change in HbA1c% will be quan-
tified by contrasting follow- up versus baseline laboratory 
test data recorded in CPRD for each exposure. Secondary 
outcomes that will also be reported at 12 months 
after baseline include HDL, LDL, total cholesterol, 
triglycerides, SBP, DBP, eGFR, body weight and BMI. 
In defining the 12- month follow- up measurement, the 
available measure that is closest in time to the 12 months 
from baseline will be used, recognising that within the 
pilot data, a median interval in HbA1c measurement of 
5 months was observed. Patients without the relevant 
measurement between 9 and 15 months will be desig-
nated as having ‘missing 12- month data’ (see missing data 
section). We will also report change in HbA1c at 6–18, 
24–30 and 36 months follow- up, again using the closest 
HbA1c measure in the 3 months before and after the 
follow- up time point of interest.
Outcomes for long- term relative effectiveness (objective 
3) will include macrovascular and microvascular condi-
tions such as CV outcomes (MI, CHF, unstable angina, 
stroke), renal outcomes (nephropathy, ESRD, 40% 
decline in eGFR from baseline29) and lower limb ampu-
tation. Additional outcomes will include hypoglycaemia, 
time- to- cessation of second- line treatment or treatment 
switching, adherence calculated according to DDD, all- 
cause mortality and number of hospital admissions (any 
reason).
The assessment of long- term outcomes will use the 
maximum available follow- up. The investigation of micro-
vascular and macrovascular complications including any 
hospitalisations will require HES data linked to CPRD, 
and so the patients in the CPRD cohort who cannot be 
linked to HES (an expected 30%–40%) will be excluded 
from this aspect of the evaluation.20 21 Hospital admis-
sions, including microvascular and macrovascular 
complications, will be identified in HES using ICD- 10 
diagnosis codes. Clinical diagnoses in primary care coded 
using Read (CPRD Gold) or SNOMED (CPRD Aurum) 
codes will be used in addition to secondary care data to 
identify outcome events. eGFR will be calculated using 
serum creatinine recorded in primary care as an input 
in the CKD- EPI formula.30 We will define nephropathy 
as new- onset albuminuria or eGFR <60 mL/min/1.73m2 
in people with eGFR ≥60 mL/min/1.73m2 and no raised 
albumin to creatinine ratio within 2 years of second- 
line treatment initiation. A 40% decline in eGFR will be 
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ESRD will be identified by primary care coding for ESRD 
and/or renal replacement therapy (RRT) by the GP.
Analytical approach
Objective 1: Describing UK treatment patterns for second-
line T2DM treatment, and summarising the results of relevant 
published RCTs to contextualise the study findings
We will describe trends in prescribing for T2DM second- 
line treatment for the duration of the study period across 
the UK and between CCGs. This analysis will update 
previous research which described the same second- line 
treatment use in the UK from 2000 to 2017, and will 
employ similar methods.4 These descriptive statistics will 
inform the assessment of the validity of the assumptions 
that underlie the overall study design. Baseline character-
istics listed in the covariates section will also be described 
for this cohort, overall and stratified by exposure group. 
We will also conduct a literature review to summarise 
published RCTs which describe the relative effectiveness of 
alternative second- line antidiabetic treatments of interest 
to this study. This will help contextualise the results of 
this observational study (cf. objectives 2 and 3). We will 
consider reasons for any possible differences between 
this observational study compared with published RCTs, 
including residual confounding and differences in the 
study populations.
Objectives 2 and 3: Instrumental variable (IV) design to estimate 
relative treatment effectiveness overall and by subgroup
Studies which apply traditional risk adjustment 
approaches with little information on case severity may 
provide biased estimates of treatment effectiveness. We 
will therefore use an IV design31 32 to estimate treatment 
effectiveness in the presence of residual confounding. 
The IV for second- line drug treatment in this study will 
be each CCG’s prescribing history, recognising that the 
choice of second- line treatment may involve the hospital 
diabetologist, the GP, other healthcare professionals, and 
the individual. We will define ‘CCG prescribing history’ 
as the proportion of people prescribed each second- line 
treatment in the CCG for the last complete calendar 
year prior to the treatment intensification currently 
under consideration. This IV encourages receipt of the 
treatment but does not have a direct effect on outcomes 
except through the treatment prescribed (figure 2). 
Using CCG prescribing history as the IV follows pharma-
coepidemiological research32 that uses provider prefer-
ence as an instrument for treatment prescribed.
In our pilot CPRD data,4 the proportions of people 
prescribed each second- line treatment regimen varied 
widely. For example, in 2014 the ranges across CCGs 
were 5%–100% (SU), 0%–90% (DPP4i) and 0%–35% 
(SGLT2i).4 These proportions have changed over time 
but similar people received different second- line treat-
ment regimens simply according to CCG prescribing 
preference or time period.4
This study’s design will exploit this wide variation in 
the choice of second- line treatment. We will use this IV to 
estimate the relative effectiveness of alternative second- 
line treatments while minimising bias from unobserved 
confounding. We will use a ‘local IV estimator’33 to allow 
for heterogeneity according to unobserved characteris-
tics (eg, lifestyle choices) as well as observed character-
istics (eg, baseline HbA1c) when reporting the relative 
effectiveness of the alternative second- line treatments 
according to individual risk factor profiles.
IV assumptions
The validity of our IV design relies on three key assump-
tions: the IV must (1) strongly predict the treatment 
prescribed; (2) be independent of baseline unmeasured 
covariates; and (3) only affect the outcome through the 
treatment prescribed.31 The IV design will lead to bias if 
the prescribing history of the CCG has a direct effect on 
the outcome. We carefully assessed whether the CCG’s 
prescribing history met the criteria for an IV. Our pilot 
data showed it was strongly associated with the second- 
line treatment regimen prescribed (assumption 1). We 
also found that prescribing history balanced the observed 
covariates (assumption 2, figure 3). We are unable to 
assess empirically whether clinicians’ prescribing history 
is independent of unmeasured confounders; however, it 
is likely that participants will attend their local GP without 
considering their prescribing history, and unlikely that 
the CCGs prescribing history would have a direct effect on 
outcomes (assumption 3). For example, it is unlikely that 
simply because a CCG shows a preference for prescribing 
SU the participants’ outcomes would be better (or worse) 
regardless of the treatment actually prescribed. We will 
reassess each assumption using the full study dataset and 
undertake sensitivity analyses to test these assumptions.
Power considerations
Power calculations were conducted prior to accessing 
study data. Clinically meaningful between- treatment 
difference in HbA1c from baseline is considered to be 
0.3 percentage points (eg, from 8.0% to 7.7%) by the 
European Medicines Agency34 and 0.5 percentage points 
by NICE.35 We based our power calculations on these 
numbers and assuming an SD of 2.4.36 We follow meth-
odological recommendations for power calculations with 
Figure 2 Instrumental variable design to be applied in this 
study comparing three options for second- line antidiabetic 
treatment. CCG, Clinical Commissioning Group; DPP4i, 
dipeptidyl peptidase- 4 inhibitors; HbA1c, haemoglobin 
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IV designs and consider that the proportion of people 
who actually receive the treatment predicted by the IV is 
80%, but also consider scenarios where the IV is weaker 
(70% compliance) and stronger (90% compliance).31 We 
require 80% power at the 5% (two- sided) level of statis-
tical significance, with a Bonferroni correction to account 
for multiple comparisons to get a familywise error rate of 
5%. Table 1 shows the requisite sample sizes of the two 
treatment groups projected to have the fewest partici-
pants (SU and SGLT2i). The study will include approx-
imately 25 700 participants (SU=6000, DPP4i=13 000, 
SGLT2i=6700) based on an initial feasibility count, which 
will be more than sufficient for detecting whether clini-
cally significant differences in the primary endpoint are 
statistically significant.
Planned analyses
We will examine the relevant trends in prescribing 
between 2014 and 2020 by CCG, and by year, and 
summarise baseline covariates using data collected prior 
to the index date for second- line treatment.
We will provide personalised estimates of treatment 
effectiveness using the local IV (LIV) approach33 37 to 
predict the counterfactual outcomes that each person 
would experience if they were prescribed each second- line 
treatment. We will use probit regression models38 to esti-
mate the propensity to receive each treatment according 
to observed characteristics, and CCG preference for each 
second- line regimen (the IV). We will estimate the rela-
tionship of each outcome with observed characteristics, 
and the propensity for each second- line treatment using 
generalised linear models (GLMs)39 for continuous and 
count outcomes. For time- to- event outcomes (eg, time to 
second- line treatment cessation, time to each microvas-
cular or macrovascular complication), we will recognise 
that the period of observation may differ across individ-
uals due to censoring. We will describe each endpoint by 
plotting Kaplan- Meier curves, and estimate each treat-
ment effect using discrete- time hazard models.40 SEs will 
be calculated with non- parametric bootstrapping, and 
will account for clustering of individuals within practices.
These models will be used to estimate the relative effect of 
prescription of SGLT2i vs SU, DPP4i versus SU and SGLT2i 
vs DPP4i for the primary and secondary outcomes. Person- 
level treatment effects will be calculated as the difference 
Figure 3 Covariate balance across levels of CCG prescribing history (this study’s IV) (2014–2017). BMI, body mass index; BP, 
blood pressure; CCG, Clinical Commissioning Group; CVD, cardiovascular disease; DPP4i, dipeptidyl peptidase- 4 inhibitors; 
eGFR, estimated glomerular filtration rate; HbA1c, haemoglobin A1c; IV, instrumental variable; SGLT2i, sodium- glucose 
cotransporter- 2 inhibitor; SU, sulfonylureas.
Table 1 Required sample size (N) for the IV design according to instrument strength (level of compliance) and magnitude of 
effect size at 80% power and 5% (two- sided) level of statistical significance
Level of compliance (IV strength)
70% 80% 90%
Effect size: between- treatment difference in mean HbA1c 
reduction baseline to 12 months
SU SGLT2i SU SGLT2i SU SGLT2i
0.3 4556 1952 3488 1495 2756 1181
0.4 2563 1098 1962 841 1550 664
0.5 1640 703 1256 538 992 425
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in predicted outcomes following prescription of the alter-
native drugs. These person- level treatment effects will be 
aggregated to report the relative effectiveness of the treat-
ments prescribed overall, and by prespecified subgroups. 
These prespecified subgroups will include: people with and 
without CV comorbidities overall and by subtype of CVD, 
people with baseline eGFR ≥60 mL/min/1.73 m2 vs base-
line eGFR <60 mL/min/1.73 m2, age groups, sex, ethnicity, 
BMI (based on WHO categorical definition41), adherence to 
metformin and baseline HbA1c levels. We will consider finer 
eGFR subgroupings, age categories and HbA1c levels based 
on descriptive statistics (objective 1) prior to any relative effec-
tiveness analyses (objectives 2–3). Any additional subgroups 
will be informed by descriptive statistics of each covariate, and 
the advice of a panel of healthcare professionals, building on 
those identified in a literature review. The clinical panellists 
will include diabetologists, GPs and practice nurses involved 
in care for people with T2DM.
Missing data
In our primary analysis, we will use a complete- case 
approach based on the main potential confounders listed 
in the covariates section. We will conduct secondary anal-
yses using complete cases for the full list of potential 
confounders, including those expected to have a high 
proportion of missing data (see covariates section), which 
we do not expect to be missing at random. Because we 
cannot assume covariate measurements are missing at 
random and the IV model is computationally intensive, 
we will not use multiple imputation.
We will adopt two main approaches based on the type 
of missingness for outcome data: (1) linear interpola-
tion using values recorded during follow- up, and (2) 
inverse probability weighting (IPW) to those people lost 
to follow- up with no subsequent outcome measure. We 
will use linear interpolation for values that are intermit-
tently missing during follow- up, for example, if HBA1c 
at 12 months is required, but the available measures are 
at 3- month and 17- month follow- up, which fall outside 
the requisite time window (9–15 months). This method 
was used in precedent diabetes research with observa-
tional data.42 For those settings, were the patient is lost 
to follow- up and there is therefore no subsequent HbA1c 
measure available, we will use IPW, reweighting the data 
for those with available observations to represent the 
group lost to follow- up, assuming therefore that the 
HbA1c data are missing at random.42 43
Sensitivity analyses
We will conduct sensitivity analyses falling under three broad 
categories: (1) Modified study population inclusion and 
exclusion criteria to evaluate the validity of our IV assump-
tions in subgroups where there is arguably less equipoise in 
the choice of second- line treatment44; (2) Comparing the 
larger primary care unlinked cohort with the primary care 
population linked to secondary care data (HES) and (3) 
Evaluating the robustness of our statistical methods.
Under the first category of sensitivity analyses, we will 
exclude people with contraindications for SU (eg, liver 
disease) who are prescribed SGLT2i, as this prescribing may 
not be due to CCG preference. We will also expand the eGFR 
exclusion to all those with eGFR <60 mL/min/1.73m2 (vs 
eGFR <30 mL/min/1.73m2 in the main analysis). In addi-
tion, we will include people who are censored or die during 
the first 60 days after a prescription for SU, DPP4i or SGLT2i 
without a prescription for metformin in the same time period 
to consider the impact of potentially misclassifying these 
people as switching from metformin monotherapy instead 
of adding on to metformin monotherapy. Under the second 
category of sensitivity analyses, we will repeat the analyses for 
objectives 1 and 2 limited to the HES- linked subpopulation 
from CPRD who are eligible for the long- term outcomes 
(objective 3). Third, we will assess the robustness of find-
ings to alternative statistical models for the LIV approach, 
outcome regressions and alternative approaches to handling 
missing data.45
Patient and public involvement
Two PP representatives were consulted when designing 
this study prior to obtaining funding. One has close family 
experience of type 1 diabetes as a carer and the other was 
recently diagnosed with T2DM. Both PP representatives have 
discussed the study with local patients and obtained future 
workshop interest. Our PP representatives reinforced that the 
study design, outcomes and interpretation should recognise 
the importance of personalising treatment choice according 
to the individual’s experience, and according to their age, 
weight, ethnicity and more general lifestyle choices. The PP 
representatives have supported plans for two study workshops 
that will inform the translation of results to patients and the 
public. The PP representatives have emphasised the impor-
tance of developing accessible preworkshop information to 
help participants prepare. The PP representatives will help 
inform the way the study presents and communicates results 
so they are accessible to patients and the general public.
Strength and limitations
This study will exploit the natural variation in prescribing 
patterns for second- line antidiabetic treatment across 
CCGs within similar groups of people by using an IV study 
design. This design minimises potential biases resulting 
from unmeasured confounders, a major limitation in 
observational research. The large and representative 
sample from UK primary care will improve the general-
isability of this study’s results and allow for stratification 
on prespecified baseline risk factors, helping patients and 
their providers choose treatments based on personal risk 
profiles to maximise clinical benefit. While the IV relies 
on three major assumptions which may limit the validity 
of our estimates, we will evaluate the strength of our 
assumptions in sensitivity analyses.
A potential limitation is that the required natural varia-
tion in prescribing may not exist for those people who are 
prescribed SGLT2i as second- line treatment because they do 

















pen: first published as 10.1136/bm






8 Bidulka P, et al. BMJ Open 2021;11:e046912. doi:10.1136/bmjopen-2020-046912
Open access 
NICE guidelines.3 We will investigate this potential source of 
bias by undertaking a sensitivity analysis excluding those in 
the SGLT2i exposure group with contraindications for SU. 
In addition, our study may be susceptible to non- differential 
outcome misclassification, as we are unable to link our data 
to additional audit datasets with more detailed outcome 
information (eg, laboratory tests) such as the Myocardial 
Ischaemia National Audit Project (MINAP).46 However, a 
previous study shows that the majority of MINAP acute MI 
events in the general England and Wales populations are also 
recorded in CPRD and HES.47
Future work
The results of this study will be used in future research which 
aims to predict long term outcomes and associated costs to 
the NHS beyond this study’s maximum follow- up. To do this, 
we will adapt a diabetes microsimulation model developed 
using observational data from the United States Veterans’ 
Affairs database48 to the UK setting. We will use a person-
alised approach to second- line treatment by using the esti-
mates of relative effectiveness within the subgroup analyses 




This study will be based in part on data from the 
CPRD obtained under licence from the UK Medicines 
and Healthcare products Regulatory Agency. The data 
are provided by patients and collected by the NHS as 
part of their care and support. The interpretation 
and conclusions contained in this protocol are those 
of the authors alone. The study was approved by the 
Independent Scientific Advisory Committee (approval 
number 20- 064) and the London School of Hygiene & 
Tropical Medicine Research Ethics Committee (refer-
ence number 21395). GPs have opted- in to contrib-
uting data to the CPRD, while individuals registered 
at these GPs may opt- out. Individual- level consent was 
not necessary since these data are deidentified.
Dissemination/outputs
This study’s outputs will be designed in collaboration with 
our expert advisory panel and PP representatives to help 
ensure this study can inform future clinical guidelines 
and care for people with T2DM. Results will be published 
open- access in peer- reviewed journals and presented at 
scientific conferences. Additional emphasis will be placed 
on the implementation of advanced quantitative methods 
in this study, which will provide general guidance for 
future studies on how the overall approach of combining 
these methods with routinely available electronic health 
data can provide insights to inform person- level care. We 
will provide recommendations via the Academic Health 
Sciences Networks to commissioners and T2DM care 
providers on how to target second- line antidiabetic treat-
ment to individuals and patient groups.
Data visualisations of key results and lay summaries 
will also be published on this website as a resource to be 
shared with key stakeholders and as accessible informa-
tion for the general public.
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